Gleave ME - Search Results

1

Heterogeneity in the inter-tumor transcriptome of high risk prostate cancer.

Wyatt AW, Mo F, Wang K, McConeghy B, Brahmbhatt S, Jong L, Mitchell DM, Johnston RL, Haegert A, Li E, Liew J, Yeung J, Shrestha R, Lapuk AV, McPherson A, Shukin R, Bell RH, Anderson S, Bishop J, Hurtado-Coll A, Xiao H, Chinnaiyan AM, Mehra R, Lin D, Wang Y, Fazli L, Gleave ME, Volik SV, Collins CC. Wyatt AW, et al. Among authors: gleave me. Genome Biol. 2014 Aug 26;15(8):426. doi: 10.1186/s13059-014-0426-y. Genome Biol. 2014. PMID: 25155515 Free PMC article.

2

Preoperative neoadjuvant androgen withdrawal therapy in prostate cancer: the Canadian experience.

Hurtado-coll A, Goldenberg SL, Klotz L, Gleave ME. Hurtado-coll A, et al. Among authors: gleave me. Urology. 2002 Sep;60(3 Suppl 1):45-51; discussion 51. doi: 10.1016/s0090-4295(02)01570-4. Urology. 2002. PMID: 12231047 Review.

3

Intermittent androgen suppression in prostate cancer: the Canadian experience.

Hurtado-Coll A, Goldenberg SL, Gleave ME, Klotz L. Hurtado-Coll A, et al. Among authors: gleave me. Urology. 2002 Sep;60(3 Suppl 1):52-6; discussion 56. doi: 10.1016/s0090-4295(02)01572-8. Urology. 2002. PMID: 12231049 Review.

4

Androgens and prostate cancer.

So AI, Hurtado-Coll A, Gleave ME. So AI, et al. Among authors: gleave me. World J Urol. 2003 Nov;21(5):325-37. doi: 10.1007/s00345-003-0373-9. Epub 2003 Oct 29. World J Urol. 2003. PMID: 14586548 Review.

5

Heat shock protein 27 increases after androgen ablation and plays a cytoprotective role in hormone-refractory prostate cancer.

Rocchi P, So A, Kojima S, Signaevsky M, Beraldi E, Fazli L, Hurtado-Coll A, Yamanaka K, Gleave M. Rocchi P, et al. Cancer Res. 2004 Sep 15;64(18):6595-602. doi: 10.1158/0008-5472.CAN-03-3998. Cancer Res. 2004. PMID: 15374973

6

Increased insulin-like growth factor I receptor expression and signaling are components of androgen-independent progression in a lineage-derived prostate cancer progression model.

Krueckl SL, Sikes RA, Edlund NM, Bell RH, Hurtado-Coll A, Fazli L, Gleave ME, Cox ME. Krueckl SL, et al. Among authors: gleave me. Cancer Res. 2004 Dec 1;64(23):8620-9. doi: 10.1158/0008-5472.CAN-04-2446. Cancer Res. 2004. PMID: 15574769

7

A phase I pharmacokinetic and pharmacodynamic study of OGX-011, a 2'-methoxyethyl antisense oligonucleotide to clusterin, in patients with localized prostate cancer.

Chi KN, Eisenhauer E, Fazli L, Jones EC, Goldenberg SL, Powers J, Tu D, Gleave ME. Chi KN, et al. Among authors: gleave me. J Natl Cancer Inst. 2005 Sep 7;97(17):1287-96. doi: 10.1093/jnci/dji252. J Natl Cancer Inst. 2005. PMID: 16145049 Clinical Trial.

8

Cyclin G-associated kinase: a novel androgen receptor-interacting transcriptional coactivator that is overexpressed in hormone refractory prostate cancer.

Ray MR, Wafa LA, Cheng H, Snoek R, Fazli L, Gleave M, Rennie PS. Ray MR, et al. Int J Cancer. 2006 Mar 1;118(5):1108-19. doi: 10.1002/ijc.21469. Int J Cancer. 2006. PMID: 16161052 Free article.

9

A novel antisense oligonucleotide inhibiting several antiapoptotic Bcl-2 family members induces apoptosis and enhances chemosensitivity in androgen-independent human prostate cancer PC3 cells.

Yamanaka K, Rocchi P, Miyake H, Fazli L, Vessella B, Zangemeister-Wittke U, Gleave ME. Yamanaka K, et al. Among authors: gleave me. Mol Cancer Ther. 2005 Nov;4(11):1689-98. doi: 10.1158/1535-7163.MCT-05-0064. Mol Cancer Ther. 2005. PMID: 16275990

10

Loss of PTEN is associated with progression to androgen independence.

Bertram J, Peacock JW, Fazli L, Mui AL, Chung SW, Cox ME, Monia B, Gleave ME, Ong CJ. Bertram J, et al. Among authors: gleave me. Prostate. 2006 Jun 15;66(9):895-902. doi: 10.1002/pros.20411. Prostate. 2006. PMID: 16496415

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

644 results

Search Page